The Antibody Society’s Post

𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 𝐓𝐨 https://lnkd.in/euN7Z8i8 𝐠𝐞𝐭 𝐰𝐞𝐥𝐥-𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 The Mexico Antibody Drug Conjugates (ADC) Market is paving the way for groundbreaking advancements in oncology. Combining the precision of antibodies with the potency of cytotoxic drugs, ADCs are redefining cancer treatment by targeting cancer cells while sparing healthy tissue. With increasing investments in biotech R&D and growing adoption of personalized medicine, Mexico is emerging as a key player in the ADC landscape. 🚀 The future of oncology is here—focused, effective, and life-changing. To Get more:https://lnkd.in/dCyCfKzM #AntibodyDrugConjugates #OncologyInnovation #BiotechMexico #TargetedTherapies #PharmaTrends"

Today on #WorldCancerResearchDay, we proudly stand with the global scientific community to underscore the critical role that research plays in improving cancer survival rates and enhancing the quality of life for patients and their families. At Zymeworks, we are deeply committed to the belief that continued research, innovation, and scientific advancement can profoundly impact the lives of cancer patients. As we advance our pipeline of multifunctional therapeutics, we honor our exceptional team of researchers, experts, and partners who are dedicated to harnessing the potential of antibody-drug conjugates (ADCs) and multispecific antibody therapeutics (MSATs) to address high unmet needs in the treatment of difficult-to-treat cancers. Together, we are driving innovation within #cancerresearch and remain unwavering in our commitment to making a meaningful difference. #AntibodyDrugConjugates #MultifunctionalTherapeutics #Biotech #DrugDevelopment #DrugDiscovery #CancerAwareness #Oncology #ResearchandDevelopment

💡 Join Crown Bioscience for an upcoming webinar to explore the significant hurdle of cancer drug resistance, one of the greatest challenges in developing effective cancer therapeutics. 💊 Dr. Rajendra Kumari will discuss the evolving landscape of drug resistance, focusing on preclinical tools and strategies that can accelerate therapeutic discovery and provide actionable insights. Attendees will gain insights into specific models developed to study resistance to targeted therapies and immunotherapeutics, along with their features and practical applications for predicting clinical outcomes. ➡️ Learn more + register here: https://buff.ly/4eagwr7 #DrugDevelopment #DrugDiscovery #DrugResistance #Oncology #TherapeuticAreas #OncologyDrugDevelopment #CancerTherapy #PreClinical #CellAndGeneTherapies

The Immuno-Oncology (IO) market is expected to grow to $154B by 2030! Here’s how next-gen IO therapies could transform cancer treatment: 💡 Combine checkpoint inhibitors with myeloid cell targeting 💡 Expand response rates and benefit more patients 💡 Address large unmet needs in cancer treatment 💡 Increase market potential for existing therapies Discover more about the future of Immuno-Oncology at ME Therapeutics: https://lnkd.in/effQ7kG4 #CancerResearch #BioTech #ImmunoOncology #HealthcareInnovation #MarketGrowth #MedicalScience #CheckpointInhibitors #CombinationTherapies #InnovativeMedicine

Immunotherapies have transformed cancer treatment, but considerable challenges remain. At Mural Oncology, we are using our advanced protein engineering capabilities to broaden the potential and reach of cytokine-based immunotherapies for people with cancer. Our lead candidate, nemvaleukin, is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose native IL-2 while mitigating the cytokine’s hallmark toxicities. It is currently in two potentially registrational trials reading out next year. Discover our pipeline and learn about the clinical trials evaluating nemvaleukin: https://bit.ly/49hUu3c #biotechnology #oncology #drugdevelopment

𝗞𝗮𝗽𝗮𝗱𝗶 𝗮𝗻𝗱 𝗡𝗲𝘅𝘁 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗧𝗲𝗮𝗺 𝗨𝗽 𝗳𝗼𝗿 𝗦𝗶𝘅 𝗣𝗵𝗮𝘀𝗲 𝟭 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀 Exciting news! Next Oncology and Oncobay have joined forces to launch a series of groundbreaking Phase 1 clinical trials. Together, we are pushing the boundaries of cancer treatment! These trials will focus on evaluating novel immuno-oncology therapies designed to unleash the immune system's power against cancer. By combining our expertise, we aim to develop safer and more effective treatments for patients battling this relentless disease. Read the full press-release here: https://lnkd.in/dNhYazmU #CancerResearch #ImmunoOncology #ClinicalTrials #Collaboration #pressrelease #article #oncology #Kapadi #clinicaltrials #clinicalresearch #pharma #biotech

Adam M. Brufsky, MD, PhD, FACP, Professor of Medicine at the University of Pittsburgh School of Medicine and Medical Director of the Magee-Women's Cancer Program, comments on the preclinical data presented at #SITC24 for BriaCell's personalized, off-the-shelf cancer #immunotherapy. https://bit.ly/3CkvZH2 #SITC24 #breastcancer #prostatecancer #noveltherapies #cancertherapies #cancerimmunotherapies #MBC #oncology #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs

𝐇𝐚𝐥𝐝𝐚 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 $𝟏𝟐𝟔𝐌 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐍𝐨𝐯𝐞𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 Halda Therapeutics Halda Therapeutics, a biotech founded by Yale professor Craig Crews, announced a $126M Series B extension to advance two cancer therapies into clinical trials. Halda is developing a novel class of therapies called Regulated Induced Proximity Targeting Chimeras (RIPTAC), which use a “hold and kill” mechanism targeting cancer cells while sparing healthy tissue. With this funding, Halda will move its lead asset, HLD-0915, for metastatic prostate cancer into Phase I trials by mid-2025, and advance another RIPTAC asset for metastatic breast cancer currently in preclinical stages. Investors in this round include RA Capital Management RA Capital Management, Deep Track Capital, and Frazier Life Sciences Frazier Life Sciences, among others, bringing total funding to $202M. #Biotech #CancerResearch #RIPTAC #Funding #ProstateCancer #BreastCancer #Innovation #ClinicalTrials #LifeSciences

If you’re developing an antibody-drug conjugate (ADC) to treat cancer, you need data-backed answers to these questions: -Is the antibody being internalized? -Where’s the therapeutic trafficked? -Is the drug actually killing cancer cells? And that’s where imaging and bioassays come in. Through a suite of imaging assays, our team of scientists can help you select your lead candidates from hundreds to a handful, making sure that the best candidate progresses to IND filing. We can provide real-time data on internalization, trafficking, tumor-cell killing, and a host of other cell functions. All of these powerful imaging assays and analyses come early on in the development process because we believe in starting smart, so you can progress fast to IND and beyond. Find out more about our assay capabilities here: https://lnkd.in/ez2YMCCD #microscopy #drugdevelopment #CDMO #CRO #ADCCDMO

🌟 Exciting collaboration in Wisconsin biotech! Wisconsin-based NorthStar Medical Radioisotopes, LLC will partner with Cellectar Biosciences, Inc. 🌟 This new partnership will integrate NorthStar's Ac-225 into Cellectar's proprietary PLE delivery platform, paving the way for groundbreaking cancer treatments. With promising preclinical results, Cellectar aims to launch clinical trials in 2025 for its radiotherapeutic candidate targeting tough-to-treat cancers like pancreatic and triple-negative breast cancer. 👏 Innovation meets reliability as NorthStar ensures a sustainable Ac-225 supply to fuel the fight against cancer. Read more: https://lnkd.in/gtCkKVJX #Biotech #CancerResearch #WisconsinInnovation